Innovative sarcoma therapy using multifaceted nano-PROTAC-induced EZH2 degradation and immunity enhancement

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Sarcomas are aggressive tumors with limited treatment options due to heterogeneity and therapy resistance.
• Enhancer of Zeste Homolog 2 (EZH2) is highly expressed in sarcomas, but direct targeting remains challenging.
• EZH2 plays a critical role in sarcoma progression through non-canonical transcriptional regulation of YAP1.

Purpose of the Study:

• To investigate the non-canonical transcriptional mechanisms of EZH2 in sarcoma.
• To develop a novel therapeutic strategy targeting EZH2 degradation and enhancing anti-tumor immunity in sarcoma.

Main Methods:

• Development of YM@VBM, a nano-PROTAC integrating a polyphenol-vanadium oxide system with an EZH2 degrader (YM281 PROTAC).
• Encapsulation of YM@VBM in methoxy polyethylene glycol-NH2 for enhanced biocompatibility and incorporation into microneedle patches for targeted delivery.
• Evaluation of YM@VBM's functionalities including reactive oxygen species generation, glutathione depletion, photothermal effects, EZH2 degradation, and anti-tumor immune response activation.

Main Results:

• YM@VBM demonstrated enhanced targeting efficacy through potent EZH2 degradation.
• The nano-PROTAC exhibited multimodal anti-sarcoma activities, including peroxidase-like activity and photothermal effects.
• YM@VBM effectively activated anti-tumor immunity by modulating myeloid-derived suppressor cells, dendritic cells, and tertiary lymphoid structures.

Conclusions:

• The study reveals non-canonical transcriptional roles of EZH2 in regulating YAP1 and driving sarcoma progression.
• YM@VBM, a versatile nano-PROTAC, offers a multifaceted approach for sarcoma treatment by targeting EZH2 and stimulating anti-tumor immunity.
• Engineered YM@VBM presents a promising therapeutic strategy for combating challenging sarcoma malignancies.